Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2025 04:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics to Present New Data Highlighting Novel ATR Inhibitor with CNS Penetration at the AACR-NCI-EORTC International Conference

VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV, FSE: 7JO0), a biopharmaceutical company advancing cancer...
April 29, 2025 15:30 ET | Source: Nouscom Srl

Nouscom Presents Positive Final Results from Completed Phase Ib/II Study of Neoantigen Immunotherapy NOUS-209 at AACR 2025, Demonstrating a Highly Potent and Durable Immune Response in Lynch Syndrome Carriers

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of cancer, especially colorectal and endometrial, to as high as 80%NOUS-209 is an off-the-shelf...
April 29, 2025 10:00 ET | Source: Rakovina Therapeutics Inc

Rakovina Therapeutics Showcases Preclinical Results of Novel AI-Discovered Cancer Therapies at AACR 2025

VANCOUVER, British Columbia, April 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing next-generation cancer therapies through...
April 29, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025
April 28, 2025 08:00 ET | Source: Evaxion Biotech

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

80% of EVX-01 vaccine targets triggered a tumor-specific immune response, a substantially higher frequency than what has been reported for other similar vaccine candidatesThe data underscores the...
April 28, 2025 08:00 ET | Source: Compass Therapeutics

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors.Combining CTX-471 with tovecimig (CTX-009) markedly increased...
April 28, 2025 07:00 ET | Source: Ampersand Biomedicines

Ampersand Biomedicines Presents Preclinical Data on AMP-410, a Novel Anti-VEGF/4-1BB Bifunctional AND-Body™ Therapeutic, at AACR 2025

Lead development candidate, AMP-410, leverages proprietary Ampersand technology to block VEGF and allosterically activate 4-1BB signaling – unlike traditional bispecific molecules – driving both...
April 25, 2025 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

SALT LAKE CITY, April 25, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced new clinical data will be shared...
April 24, 2025 06:45 ET | Source: BioNTech SE

BioNTech präsentiert auf der AACR-Jahrestagung 2025 klinische und präklinische Daten zu mRNA- und Immunonkologie-Fokus-Programmen

MAINZ, Deutschland, 24. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Association for Cancer Research...
April 24, 2025 06:45 ET | Source: BioNTech SE

BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025

MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer...